Physician profile
Ivan A Calderon
NPI 1043453749
$7,426.91
in general payments reported to CMS, 2019-2025
36 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $260 · 2021: $1,105 · 2022: $1,392 · 2023: $1,512 · 2024: $1,170 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.21 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $993.24 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $719.30 | 2019-2025 | |
| Novo Nordisk INC | $717.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $602.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $566.71 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.51 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $300.95 | 2019-2021 | |
| Amgen INC. | $280.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $212.74 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $184.14 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $139.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $136.50 | 2023 | Descovy |
| Esperion Therapeutics, INC. | $133.13 | 2021-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.03 | 2024-2025 | Caplyta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $101.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Dynavax Technologies Corporation | $100.84 | 2024-2025 | Heplisav-B |
| Abiomed | $98.18 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $94.88 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $83.80 | 2021 | |
| Astellas Pharma US INC | $81.31 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $70.20 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $53.41 | 2020-2022 | |
| Janssen Biotech, INC. | $49.33 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $40.24 | 2022 | |
| Allergan, INC. | $38.58 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.60 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $29.45 | 2019-2020 | |
| Si-Bone, INC. | $19.25 | 2021 | |
| Ardelyx, INC. | $16.73 | 2024 | Ibsrela |
| Hologic Sales and Service, LLC | $16.45 | 2021 | |
| Globus Medical, INC. | $16.45 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $16.34 | 2022 | |
| Mylan Specialty L.P. | $12.58 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.46 | 2022 | |
| Inogen, INC. | $7.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.